Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 1990;82:147-153

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hirooka, Y.
Right arrow Articles by Nakamura, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hirooka, Y.
Right arrow Articles by Nakamura, M.

Circulation, Vol 82, 147-153, Copyright © 1990 by American Heart Association


ARTICLES

Attenuated forearm vasodilative response to intra-arterial atrial natriuretic peptide in patients with heart failure

Y Hirooka, A Takeshita, T Imaizumi, S Suzuki, M Yoshida, S Ando and M Nakamura
Research Institute of Angiocardiology, Faculty of Medicine, Kyushu University, Fukuoka, Japan.

It has been shown that renal responses to atrial natriuretic peptide (ANP) are markedly attenuated in patients with heart failure. This study aimed to determine if vasodilative response to ANP is altered in patients with heart failure. In patients with heart failure (n = 7) and age-matched normal subjects (n = 7), forearm blood flow was measured using a strain-gauge plethysmograph during intra-arterial infusion of alpha-human ANP (50, 100, 200, and 400 ng/min) or nitroglycerin (100, 200, 400, and 600 ng/min). Forearm vasodilatation evoked with intra- arterial alpha-human ANP in patients with heart failure was considerably less (p less than 0.01) than that in normal subjects. In contrast, nitroglycerin produced comparable forearm vasodilatation in the two groups. Plasma ANP and cyclic guanosine monophosphate (GMP) levels at rest were higher in patients with heart failure than in normal subjects (p less than 0.05 for both), but the increases in plasma ANP and cyclic GMP in the venous effluents during intra-arterial ANP infusion did not differ between the two groups. These results indicate that the direct vasodilative effect of ANP on forearm vessels was attenuated in patients with heart failure as compared with that in normal subjects. The mechanisms responsible for this alteration are not clear but might involve mechanisms other than down-regulation of the ANP receptors because the increases in venous plasma cyclic GMP caused by intra-arterial ANP were comparable between patients with heart failure and normal subjects.


This article has been cited by other articles:


Home page
J Am Coll CardiolHome page
P. R. Forfia, M. Lee, R. S. Tunin, M. Mahmud, H. C. Champion, and D. A. Kass
Acute Phosphodiesterase 5 Inhibition Mimics Hemodynamic Effects of B-Type Natriuretic Peptide and Potentiates B-Type Natriuretic Peptide Effects in Failing But Not Normal Canine Heart
J. Am. Coll. Cardiol., March 13, 2007; 49(10): 1079 - 1088.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
G. Singh, R. E. Kuc, J. J. Maguire, M. Fidock, and A. P. Davenport
Novel Snake Venom Ligand Dendroaspis Natriuretic Peptide Is Selective for Natriuretic Peptide Receptor-A in Human Heart: Downregulation of Natriuretic Peptide Receptor-A in Heart Failure
Circ. Res., July 21, 2006; 99(2): 183 - 190.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
T. Kishi, Y. Hirooka, A. Masumoto, K. Ito, Y. Kimura, K. Inokuchi, T. Tagawa, H. Shimokawa, A. Takeshita, and K. Sunagawa
Rho-Kinase Inhibitor Improves Increased Vascular Resistance and Impaired Vasodilation of the Forearm in Patients With Heart Failure
Circulation, May 31, 2005; 111(21): 2741 - 2747.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
N. L.M. Cruden, K. A.A. Fox, C. A. Ludlam, N. R. Johnston, and D. E. Newby
Neutral Endopeptidase Inhibition Augments Vascular Actions of Bradykinin in Patients Treated With Angiotensin-Converting Enzyme Inhibition
Hypertension, December 1, 2004; 44(6): 913 - 918.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
M. Kuhn, M. Voss, D. Mitko, J. Stypmann, C. Schmid, N. Kawaguchi, F. Grabellus, and H. A. Baba
Left ventricular assist device support reverses altered cardiac expression and function of natriuretic peptides and receptors in end-stage heart failure
Cardiovasc Res, November 1, 2004; 64(2): 308 - 314.
[Abstract] [Full Text] [PDF]


Home page
J CARDIOVASC PHARMACOL THERHome page
M. Komarek, A. Bernheim, R. Schindler, R. Steden, W. Kiowski, and H. P. B.-L. Rocca
Vascular Effects of Natriuretic Peptides in Healthy Men
Journal of Cardiovascular Pharmacology and Therapeutics, October 1, 2004; 9(4): 263 - 270.
[Abstract] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
M. Schmitt, P. Gunaruwan, N. Payne, J. Taylor, L. Lee, A. J.M. Broadley, A. K. Nightingale, J. R. Cockcroft, A. D. Struthers, J. V. Tyberg, et al.
Effects of Exogenous and Endogenous Natriuretic Peptides on Forearm Vascular Function in Chronic Heart Failure
Arterioscler. Thromb. Vasc. Biol., May 1, 2004; 24(5): 911 - 917.
[Abstract] [Full Text]


Home page
Circ. Res.Home page
M. Kuhn
Structure, Regulation, and Function of Mammalian Membrane Guanylyl Cyclase Receptors, With a Focus on Guanylyl Cyclase-A
Circ. Res., October 17, 2003; 93(8): 700 - 709.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
M. Schmitt, A. J.M. Broadley, A. K. Nightingale, N. Payne, P. Gunaruwan, J. Taylor, L. Lee, J. Cockcroft, A. D. Struthers, and M. P. Frenneaux
Atrial Natriuretic Peptide Regulates Regional Vascular Volume and Venous Tone in Humans
Arterioscler. Thromb. Vasc. Biol., October 1, 2003; 23(10): 1833 - 1838.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
W. Johnson, T. Omland, C. Hall, C. Lucas, O. L. Myking, C. Collins, M. Pfeffer, J.-L. Rouleau, and L. W. Stevenson
Neurohormonal activation rapidly decreases after intravenous therapy withdiuretics and vasodilators for class IV heart failure
J. Am. Coll. Cardiol., May 15, 2002; 39(10): 1623 - 1629.
[Abstract] [Full Text] [PDF]


Home page
HeartHome page
M Kuhn, R Holtwick, H A Baba, J C Perriard, W Schmitz, and E Ehler
Progressive cardiac hypertrophy and dysfunction in atrial natriuretic peptide receptor (GC-A) deficient mice
Heart, April 1, 2002; 87(4): 368 - 374.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
P.R Kalra, S.D Anker, A.D Struthers, and A.J.S Coats
The role of C-type natriuretic peptide in cardiovascular medicine
Eur. Heart J., June 2, 2001; 22(12): 997 - 1007.
[PDF]


Home page
ANGIOLOGYHome page
A. Cortella, S. Zambon, G. Sartore, F. Piarulli, A. Calabro, G. Crepaldi, and E. Manzato
Calf and Forearm Blood Flow in Hypercholesterolemic Patients
Angiology, April 1, 2000; 51(4): 309 - 318.
[Abstract] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
T. Matsumoto, A. Wada, T. Tsutamoto, T. Omura, H. Yokohama, M. Ohnishi, I. Nakae, M. Takahashi, and M. Kinoshita
Vasorelaxing effects of atrial and brain natriuretic peptides on coronary circulation in heart failure
Am J Physiol Heart Circ Physiol, June 1, 1999; 276(6): H1935 - H1942.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Cell Physiol.Home page
N. Stephens, M. J. Drinkhill, A. S. Hall, S. G. Ball, and A. M. Heagerty
Structure and in vitro function of human subcutaneous small arteries in mild heart failure
Am J Physiol Cell Physiol, May 1, 1998; 274(5): C1298 - C1305.
[Abstract] [Full Text] [PDF]